Table 2.
Normoxic mdx Hemodyanmic Data.
| Baseline | Dobutamine | Esmolol | Significance | |
|---|---|---|---|---|
| Heart Rate (bpm) | 490 ± 22.4 (5) | 574 ± 10.1 (5) | 442 ± 33.4 (5) | c |
| End-Systolic Pressure (mmHg) | 87.5 ± 6.06 (5) | 92.1 ± 9.9 (5) | 63.9 ± 6.31 (5) | c,e |
| End-Diastolic Pressure (mmHg) | 9.46 ± 2.23 (5) | 9.58 ± 2.26 (5) | 10.3 ± 2.29 (5) | |
| Maximum dP/dt (mmHg/s) | 7105 ± 960 (5) | 10269 ± 1788 (5) | 3473 ± 411 (5) | e |
| Minimum dP/dt (mmHg/s) | 6646 ± 468 (5) | 6713 ± 633 (5) | 3290 ± 531 (5) | c,d,e |
| Tau (msec) | 9.32 ± 1.17 (5) | 8.11 ± 0.981 (5) | 15.5 ± 3.04 (5) | |
| End-Diastolic Volume (μl) | 37.2 ± 4.59 (5) | 40 ± 3.89 (5) | 60.1 ± 11 (5) | |
| End-Systolic Volume (μl) | 24.6 ± 6.64 (5) | 20.7 ± 5.5 (5) | 53.6 ± 11.2 (5) | |
| Cardiac Output (μl/min) | 11217 ± 1107 (5) | 15716 ± 2654 (5) | 8072 ± 1368 (5) | |
| PRSW (mmHg⋅μl/μl) | 74.3 ± 7.46 (5) | 78.6 ± 11.6 (5) | 20.9 ± 4.25 (4) |
Significant testing by three-way ANOVA with genotype, oxygen therapy protocol, and hemodynamic protocol treatment as factors with Tukey post-hoc test. a; signifies difference between baseline and dobutamine with normoxic protocol in mdx mice; b: signifies difference between baseline and esmolol with normoxic treatment in mdx mice; c: signifies an overall genotype effect; d: represents an overall difference between normoxia and HBOT treatment; e: represents an overall difference between normoxia and hyperoxic treatment.